Meeting Report: Psoriasis Stratification to Optimise Relevant Therapy Showcase

PSORT Consortium

Research output: Contribution to journalShort surveypeer-review


A stratified medicine approach for the treatment of psoriasis promises greater certainty of clinical decision making through prediction of response on the basis of clinical, pharmacological, and -omics data from an individual patient. As yet, there is no predictive model for treatment response in routine clinical use for psoriasis. The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium is a United Kingdom Medical Research Council‒funded, academic‒industrial stratified medicine consortium established with the objective of discovering the predictors and stratifiers of response of psoriasis to biologic therapies. A showcase meeting was convened and attended by 80 stakeholders at the Royal College of Physicians, London, United Kingdom on 18 November 2019. The purpose was to disseminate the research findings from the PSORT consortium discovered thus far. This report summarizes the presentations made on the day and the significant advances made by PSORT toward a stratified medicine approach to the management of psoriasis.

Original languageEnglish
JournalThe Journal of investigative dermatology
Early online date23 Mar 2021
Publication statusPublished - 23 Mar 2021


Dive into the research topics of 'Meeting Report: Psoriasis Stratification to Optimise Relevant Therapy Showcase'. Together they form a unique fingerprint.

Cite this